Swarupananda Mukherjee
Research Subjects
Swarupananda Mukherjee has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Dipanjan Karati
Techno India University
18 shared publications- Bhupendra Gopalbhai Prajapati
Parul University
8 shared publications - Dipanjan Karati
Department of Pharmaceutical Technology School of Pharmacy Techno India University, West Bengal Kolkata India
8 shared publications Souvik Roy
Department of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata- Group of Institutions, Kolkata, India
7 shared publicationsAyon Dutta
Brainware University
4 shared publications- Biswajit Basu
Department of Pharmaceutical Technology, School of Health & Medical Sciences, Adamas University, Barasat, Kolkata, India
4 shared publications
Latest Publications
- 12 November 2026
- Published by Taylor & Francis in Therapeutic Delivery
- p. 1-19
Alginate-based long-acting injectable formulations: recent advances, biomedical applications, and translational challenges
- 12 November 2026
- Published by Taylor & Francis in Therapeutic Delivery
- p. 1-19
Alginate-based long-acting injectable formulations: recent advances, biomedical applications, and translational challenges
- 28 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20, 1-15
From Light to Life: Potential Utility of Quantum Dots in Drug Delivery and Advanced Sciences
Driven by demand for new materials with intriguing features, the discipline of materials science and technology is rapidly advancing and now makes a significant contribution to research in nanoscale science. A material is classified based on the number of dimensions outside the nanoscale range in which particles are contained. Artificial nanocrystals with confinement in all three dimensions and nanometer-scale electron-transport capabilities are called quantum dots (QDs). Because of their distinct physical and optical properties, QDs have captivated scientists worldwide since their discovery in 1981. Their potential for use in a variety of optical-based biological applications makes them extremely desirable. QDs, which are nanocrystals smaller than 10 nm, possess unique optical, electrical, and chemical properties due to quantum confinement. QDs can be synthesised via colloidal, hydrothermal, and biomimetic methods. They have potential uses in biosensors, bioimaging, wastewater treatment, drug delivery, and quantum computing. QDs’ basic composition, size, surface functionalization, and dose are the primary variables affecting their biocompatibility and toxicity. Potential toxicity from oxidative stress and heavy metal release can be significantly reduced by using appropriate surface coating and encapsulation techniques. In 2011, the first human clinical trial using QD technology was approved by the USFDA. This innovative phase I exploratory trial used silica-based near-infrared QDs in a small number of patients with melanoma. This review provides a basic introduction to QDs, their preparation process, drug release mechanism, applications, challenges, toxicity concerns, and clinical trials. The role of artificial intelligence (AI), machine learning (ML), and deep learning in QD design, optimization, biocompatibility enhancement, and augmentation of therapeutic performance has been the focus, leading to a novel perspective.
- 28 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20, 1-15
From Light to Life: Potential Utility of Quantum Dots in Drug Delivery and Advanced Sciences
Driven by demand for new materials with intriguing features, the discipline of materials science and technology is rapidly advancing and now makes a significant contribution to research in nanoscale science. A material is classified based on the number of dimensions outside the nanoscale range in which particles are contained. Artificial nanocrystals with confinement in all three dimensions and nanometer-scale electron-transport capabilities are called quantum dots (QDs). Because of their distinct physical and optical properties, QDs have captivated scientists worldwide since their discovery in 1981. Their potential for use in a variety of optical-based biological applications makes them extremely desirable. QDs, which are nanocrystals smaller than 10 nm, possess unique optical, electrical, and chemical properties due to quantum confinement. QDs can be synthesised via colloidal, hydrothermal, and biomimetic methods. They have potential uses in biosensors, bioimaging, wastewater treatment, drug delivery, and quantum computing. QDs’ basic composition, size, surface functionalization, and dose are the primary variables affecting their biocompatibility and toxicity. Potential toxicity from oxidative stress and heavy metal release can be significantly reduced by using appropriate surface coating and encapsulation techniques. In 2011, the first human clinical trial using QD technology was approved by the USFDA. This innovative phase I exploratory trial used silica-based near-infrared QDs in a small number of patients with melanoma. This review provides a basic introduction to QDs, their preparation process, drug release mechanism, applications, challenges, toxicity concerns, and clinical trials. The role of artificial intelligence (AI), machine learning (ML), and deep learning in QD design, optimization, biocompatibility enhancement, and augmentation of therapeutic performance has been the focus, leading to a novel perspective.
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20, 1-20
Targeted Delivery of RNA-based Therapeutics by Lipid Nanoparticles
Lipid Nanoparticles (LNPs) have emerged as adaptable and effective delivery systems for RNA-based therapies, transforming contemporary medicine. This article covers the design, processes, and therapeutic potential of LNPs for RNA delivery. LNPs improve RNA encapsulation, stability, and targeted cellular delivery. Lipid nanoparticles protect RNA molecules from enzymatic degradation, enable endosomal escape, and allow cytoplasmic release for gene control or functional translation. Various RNA types are delivered using LNPs for specific therapeutic applications, such as mRNA for vaccines and protein replacement, siRNA for gene silencing in diverse genetic and oncological conditions, miRNA for gene expression modulation, and CRISPR/Cas9 components for targeted gene editing. LNP-mediated RNA therapies have demonstrated efficacy across a diverse array of diseases. The design and optimization of LNPs depend on several factors. In vivo studies and preclinical models have confirmed their safety and efficacy, leading to successful clinical trials and FDA-approved RNAbased therapies. However, challenges encompass immunogenicity, limited tissue selectivity, substantial production requirements, and longer safety duration. Recent advancements in ionizable lipid chemistry, microfluidic formulation, and targeted delivery techniques are broadening the therapeutic potential of LNPs, reinforcing their significance as essential carriers in the forthcoming era of precision RNA medicine.
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20, 1-20
Targeted Delivery of RNA-based Therapeutics by Lipid Nanoparticles
Lipid Nanoparticles (LNPs) have emerged as adaptable and effective delivery systems for RNA-based therapies, transforming contemporary medicine. This article covers the design, processes, and therapeutic potential of LNPs for RNA delivery. LNPs improve RNA encapsulation, stability, and targeted cellular delivery. Lipid nanoparticles protect RNA molecules from enzymatic degradation, enable endosomal escape, and allow cytoplasmic release for gene control or functional translation. Various RNA types are delivered using LNPs for specific therapeutic applications, such as mRNA for vaccines and protein replacement, siRNA for gene silencing in diverse genetic and oncological conditions, miRNA for gene expression modulation, and CRISPR/Cas9 components for targeted gene editing. LNP-mediated RNA therapies have demonstrated efficacy across a diverse array of diseases. The design and optimization of LNPs depend on several factors. In vivo studies and preclinical models have confirmed their safety and efficacy, leading to successful clinical trials and FDA-approved RNAbased therapies. However, challenges encompass immunogenicity, limited tissue selectivity, substantial production requirements, and longer safety duration. Recent advancements in ionizable lipid chemistry, microfluidic formulation, and targeted delivery techniques are broadening the therapeutic potential of LNPs, reinforcing their significance as essential carriers in the forthcoming era of precision RNA medicine.
- 14 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Food, Nutrition & Agriculture
- Vol. 17, 1-21
Ethnobotanical, Phyto-pharmacological, and Bio-economic Prospects of Phyllostachys edulis (Carrière) J.Houz.: Review of Recent Advances
Background: Phyllostachys edulis (Carrière) J.Houz. (Moso bamboo) has historically been recognised as a structural timber resource ("Green Gold"), overshadowing its significant potential as a reservoir of therapeutic bioactive compounds. This review aims to thoroughly integrate current knowledge on phytochemistry, pharmacological mechanisms of action, safety issues, and agricultural and industrial aspects to identify future research areas. Methods: The literature search was conducted across five major databases (PubMed, ScienceDirect, Google Scholar, ResearchGate, and Semantic Scholar) covering the period from January 2019 to December 2025. Following rigorous screening of 630 initial records, 101 primary studies that met strict inclusion criteria for phytochemical characterisation and molecular pharmacology were synthesised. Important articles published before 2019 were included to provide essential background and context. Results: Phytochemical analysis reveals a unique radial metabolite gradient, dominated by stable flavone C-glycosides (isoorientin, vitexin) and immunomodulatory polysaccharides (BSDF-1). Mechanistic evidence supports their efficacy in regulating metabolic syndrome via the PI3K/Akt signalling axis and in mitigating chronic inflammation by suppressing the NLRP3 inflammasome. Additionally, novel sterol derivatives isolated from shoot residues exhibit significant cytotoxicity against the MCF-7 breast cancer cell line. Discussion: Clinical translation is currently impeded by the poor oral bioavailability of Cglycosides and the species' capacity for heavy metal bioaccumulation (Pb, Cd) in polluted soils. Conclusion: P. edulis represents a validated therapeutic bioresource with distinct advantages in metabolic and neuroprotective interventions. Future utilisation must prioritise the development of nano-delivery systems to overcome bioavailability barriers, the implementation of rigorous heavy metal monitoring to ensure safety within a circular bioeconomy, and well-designed clinical studies, pharmacokinetic optimisation, standardisation of bioactive constituents, and advanced drugdelivery strategies to facilitate clinical translation.
- 14 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Food, Nutrition & Agriculture
- Vol. 17, 1-21
Ethnobotanical, Phyto-pharmacological, and Bio-economic Prospects of Phyllostachys edulis (Carrière) J.Houz.: Review of Recent Advances
Background: Phyllostachys edulis (Carrière) J.Houz. (Moso bamboo) has historically been recognised as a structural timber resource ("Green Gold"), overshadowing its significant potential as a reservoir of therapeutic bioactive compounds. This review aims to thoroughly integrate current knowledge on phytochemistry, pharmacological mechanisms of action, safety issues, and agricultural and industrial aspects to identify future research areas. Methods: The literature search was conducted across five major databases (PubMed, ScienceDirect, Google Scholar, ResearchGate, and Semantic Scholar) covering the period from January 2019 to December 2025. Following rigorous screening of 630 initial records, 101 primary studies that met strict inclusion criteria for phytochemical characterisation and molecular pharmacology were synthesised. Important articles published before 2019 were included to provide essential background and context. Results: Phytochemical analysis reveals a unique radial metabolite gradient, dominated by stable flavone C-glycosides (isoorientin, vitexin) and immunomodulatory polysaccharides (BSDF-1). Mechanistic evidence supports their efficacy in regulating metabolic syndrome via the PI3K/Akt signalling axis and in mitigating chronic inflammation by suppressing the NLRP3 inflammasome. Additionally, novel sterol derivatives isolated from shoot residues exhibit significant cytotoxicity against the MCF-7 breast cancer cell line. Discussion: Clinical translation is currently impeded by the poor oral bioavailability of Cglycosides and the species' capacity for heavy metal bioaccumulation (Pb, Cd) in polluted soils. Conclusion: P. edulis represents a validated therapeutic bioresource with distinct advantages in metabolic and neuroprotective interventions. Future utilisation must prioritise the development of nano-delivery systems to overcome bioavailability barriers, the implementation of rigorous heavy metal monitoring to ensure safety within a circular bioeconomy, and well-designed clinical studies, pharmacokinetic optimisation, standardisation of bioactive constituents, and advanced drugdelivery strategies to facilitate clinical translation.
- Open Access
- 10 September 2026
- Published by Springer Nature in Discover Chemistry
- Vol. 3 (1) , 508
Correction: Computational exploration of novel indanone-pyrazole fused schiff base scaffolds as potential EGFR inhibitors for anticancer therapy
- 10 September 2026
- Published by Springer Nature in Discover Chemistry
- Vol. 3 (1) , 508
Open AccessCorrection: Computational exploration of novel indanone-pyrazole fused schiff base scaffolds as potential EGFR inhibitors for anticancer therapy
- Open Access
- 17 June 2026
- Published by Wiley in Smart Molecules
- Vol. 4 (3)
Applications of chitosan derivatives as adjuvants for nanoparticle‐based vaccines: A comprehensive review
The development of safe and effective vaccines remains a critical priority in modern medicine. Traditional adjuvants, while effective in enhancing immune responses, often suffer from limitations including local reactogenicity, limited mucosal immunity, and instability of antigens. Chitosan, a natural polysaccharide derived from chitin, and its derivatives have emerged as promising candidates for nanoparticle‐based vaccine delivery due to their biocompatibility, biodegradability, mucoadhesive properties, and intrinsic immunostimulatory activity. Chemical modifications of chitosan, such as trimethylation, quaternization, and thiolation, enhance its solubility, stability, and immune modulatory functions. Chitosan derivative nanoparticles (CDNPs) facilitate efficient antigen encapsulation, protect labile biomolecules, and promote uptake by antigen‐presenting cells. They can trigger both humoral and cellular immune responses, particularly through mucosal administration routes. This review comprehensively discusses the physicochemical properties of chitosan derivatives, mechanisms of immune enhancement, methods for nanoparticle preparation, applications in preclinical and clinical vaccine studies, and challenges for translation to human use. Insights from recent literature suggest that CDNPs hold significant potential to revolutionize vaccine delivery platforms, especially for mucosal vaccines and next‐generation immunotherapeutics.
- 17 June 2026
- Published by Wiley in Smart Molecules
- Vol. 4 (3)
Open AccessApplications of chitosan derivatives as adjuvants for nanoparticle‐based vaccines: A comprehensive review
The development of safe and effective vaccines remains a critical priority in modern medicine. Traditional adjuvants, while effective in enhancing immune responses, often suffer from limitations including local reactogenicity, limited mucosal immunity, and instability of antigens. Chitosan, a natural polysaccharide derived from chitin, and its derivatives have emerged as promising candidates for nanoparticle‐based vaccine delivery due to their biocompatibility, biodegradability, mucoadhesive properties, and intrinsic immunostimulatory activity. Chemical modifications of chitosan, such as trimethylation, quaternization, and thiolation, enhance its solubility, stability, and immune modulatory functions. Chitosan derivative nanoparticles (CDNPs) facilitate efficient antigen encapsulation, protect labile biomolecules, and promote uptake by antigen‐presenting cells. They can trigger both humoral and cellular immune responses, particularly through mucosal administration routes. This review comprehensively discusses the physicochemical properties of chitosan derivatives, mechanisms of immune enhancement, methods for nanoparticle preparation, applications in preclinical and clinical vaccine studies, and challenges for translation to human use. Insights from recent literature suggest that CDNPs hold significant potential to revolutionize vaccine delivery platforms, especially for mucosal vaccines and next‐generation immunotherapeutics.
- 14 May 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (5)
Design and Optimization of Glimepiride Loaded Lipid Nanocarriers: Characterization and In vivo Evaluation
- 14 May 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (5)
Design and Optimization of Glimepiride Loaded Lipid Nanocarriers: Characterization and In vivo Evaluation
- 6 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (4) , 203
Design, Optimization and Pharmacokinetic Profiling of BCS Class II Drug Loaded Oral Self Nanoemulsifying System
The orally administered self nano emulsifying drug delivery system (SNEDDS), an uniform blend with nano scaled globules, is composed of oil, surfactant and
- 6 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (4) , 203
Design, Optimization and Pharmacokinetic Profiling of BCS Class II Drug Loaded Oral Self Nanoemulsifying System
The orally administered self nano emulsifying drug delivery system (SNEDDS), an uniform blend with nano scaled globules, is composed of oil, surfactant and
- 4 May 2026
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 17 (5) , 395-404
Statistical optimization and characterization of diacerein-loaded Eudragit S-100 nanoparticles using a 3 2 factorial design for rheumatoid arthritis therapy
This study focused on developing an effective Rheumatoid Arthritis (RA) treatment by creating diacerein-loaded nanoparticles. The goal was to create a more efficient RA treatment with fewer side effects, something conventional treatments fail to achieve. Using the solvent evaporation technique, the researchers produced nanoparticles and formulated them, which they optimized using DOE (Design of Experiments). They also analyzed their nanoparticle formulations through three methods: particle size, entrapment efficiency, and in vitro drug release. Their results indicate controlled drug release and desirable physical-chemical properties that should lead to greater bioavailability, which is a good thing because it leads to less waste. The in-vitro studies show that when using diacerein delivered through nanoparticles, there will be a greater anti-inflammatory response from chondrocytes than if diacerein were administered alone. Therefore, this study provides evidence that nanoparticles can be used to treat RA, improving drug effectiveness, decreasing systemic toxicity, and improving patient compliance.
- 4 May 2026
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 17 (5) , 395-404
Statistical optimization and characterization of diacerein-loaded Eudragit S-100 nanoparticles using a 3 2 factorial design for rheumatoid arthritis therapy
This study focused on developing an effective Rheumatoid Arthritis (RA) treatment by creating diacerein-loaded nanoparticles. The goal was to create a more efficient RA treatment with fewer side effects, something conventional treatments fail to achieve. Using the solvent evaporation technique, the researchers produced nanoparticles and formulated them, which they optimized using DOE (Design of Experiments). They also analyzed their nanoparticle formulations through three methods: particle size, entrapment efficiency, and in vitro drug release. Their results indicate controlled drug release and desirable physical-chemical properties that should lead to greater bioavailability, which is a good thing because it leads to less waste. The in-vitro studies show that when using diacerein delivered through nanoparticles, there will be a greater anti-inflammatory response from chondrocytes than if diacerein were administered alone. Therefore, this study provides evidence that nanoparticles can be used to treat RA, improving drug effectiveness, decreasing systemic toxicity, and improving patient compliance.